(CercleFinance.com) – GenSight Biologics announces that the results of the REFLECT phase III clinical study of its Lumevoq gene therapy will be presented at the Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) being held in Austin, Texas, February 12-17.
Nancy Newman (Emory University School of Medicine in Atlanta), international coordinating investigator of the study, will present these results in light of the natural history of Leber Hereditary Optic Neuropathy (LHON) and the two RESCUE and REVERSE studies.
Also, Benson Chen, from the University of Cambridge in the United Kingdom, will present the impact of LHON on the quality of life of patients and their families as part of the virtual NANOS session which will be available on demand from the March 9 to May 31.